派林生物静注人免疫球蛋白补充申请获受理

Core Viewpoint - Palin Biopharma (000403) announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., received a notice of acceptance from the National Medical Products Administration for the supplemental application of intravenous immunoglobulin products [1] Group 1: Company Developments - The supplemental application for intravenous immunoglobulin in 2.5g/bottle, 5g/bottle, and 10g/bottle formats has been accepted [1] - The primary indications for intravenous immunoglobulin include primary immunoglobulin deficiency, secondary immunoglobulin deficiency diseases, and autoimmune diseases [1] Group 2: Industry Context - Current domestic companies with marketing approval for intravenous immunoglobulin (5g/bottle, 10%, 50ml) include Chengdu Rongsheng Pharmaceutical Co., Ltd., Guizhou Taibang Biologic Products Co., Ltd., and China Resources Boya Biopharmaceutical Group Co., Ltd. [1]